

Hadine Joffe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5763013/publications.pdf>

Version: 2024-02-01

137
papers

7,318
citations

47006

47
h-index

60623

81
g-index

137
all docs

137
docs citations

137
times ranked

6508
citing authors

#	ARTICLE	IF	CITATIONS
1	Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition. JAMA Internal Medicine, 2015, 175, 531.	5.1	601
2	Sociodemographic predictors of antenatal and postpartum depressive symptoms among women in a medical group practice. Journal of Epidemiology and Community Health, 2006, 60, 221-227.	3.7	489
3	Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge?. Biological Psychiatry, 1998, 44, 798-811.	1.3	246
4	Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women. JAMA - Journal of the American Medical Association, 2011, 305, 267.	7.4	199
5	Estrogen therapy selectively enhances prefrontal cognitive processes. Menopause, 2006, 13, 411-422.	2.0	195
6	Ovarian Hormone Fluctuation, Neurosteroids, and HPA Axis Dysregulation in Perimenopausal Depression: A Novel Heuristic Model. American Journal of Psychiatry, 2015, 172, 227-236.	7.2	166
7	Sleep During the Perimenopause: A SWAN Story. Obstetrics and Gynecology Clinics of North America, 2011, 38, 567-586.	1.9	161
8	Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause, 2002, 9, 392-398.	2.0	160
9	Low-Dose Estradiol and the Serotonin-Norepinephrine Reuptake Inhibitor Venlafaxine for Vasomotor Symptoms. JAMA Internal Medicine, 2014, 174, 1058.	5.1	160
10	Evaluation and Management of Sleep Disturbance during the Menopause Transition. Seminars in Reproductive Medicine, 2010, 28, 404-421.	1.1	155
11	Menopause-associated Symptoms and Cognitive Performance: Results From the Study of Women's Health Across the Nation. American Journal of Epidemiology, 2010, 171, 1214-1224.	3.4	143
12	Clinical Advances in Sex- and Gender-Informed Medicine to Improve the Health of All. JAMA Internal Medicine, 2020, 180, 574.	5.1	132
13	Impact of oral contraceptive pill use on premenstrual mood: Predictors of improvement and deterioration. American Journal of Obstetrics and Gynecology, 2003, 189, 1523-1530.	1.3	124
14	Gains in Body Fat and Vasomotor Symptom Reporting Over the Menopausal Transition: The Study of Women's Health Across the Nation. American Journal of Epidemiology, 2009, 170, 766-774.	3.4	122
15	Trajectory Clustering of Estradiol and Follicle-Stimulating Hormone during the Menopausal Transition among Women in the Study of Women's Health across the Nation (SWAN). Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2872-2880.	3.6	122
16	Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause, 2018, 25, 1069-1085.	2.0	122
17	Sex and Gender Differences in Health: What the COVID-19 Pandemic Can Teach Us. Annals of Internal Medicine, 2020, 173, 385-386.	3.9	119
18	Valproate Is Associated with New-Onset Oligoamenorrhea with Hyperandrogenism in Women with Bipolar Disorder. Biological Psychiatry, 2006, 59, 1078-1086.	1.3	117

#	ARTICLE	IF	CITATIONS
19	Gender differences in bipolar disorder: retrospective data from the first 500 STEP-BD participants. <i>Bipolar Disorders</i> , 2005, 7, 465-470.	1.9	116
20	Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women. <i>Menopause</i> , 2006, 13, 780-786.	2.0	115
21	Eszopiclone in Patients With Insomnia During Perimenopause and Early Postmenopause. <i>Obstetrics and Gynecology</i> , 2006, 108, 1402-1410.	2.4	114
22	A Reproductive Subtype of Depression. <i>Harvard Review of Psychiatry</i> , 2009, 17, 72-86.	2.1	112
23	Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms. <i>JAMA Internal Medicine</i> , 2016, 176, 913.	5.1	110
24	Vasomotor Symptoms and Insulin Resistance in the Study of Women's Health Across the Nation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3487-3494.	3.6	100
25	Increased Estradiol and Improved Sleep, But Not Hot Flashes, Predict Enhanced Mood during the Menopausal Transition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1044-E1054.	3.6	90
26	Psychotropic-Induced Hyperprolactinemia: A Clinical Review. <i>Psychosomatics</i> , 2014, 55, 29-36.	2.5	90
27	Vasomotor Symptoms and Lipid Profiles in Women Transitioning Through Menopause. <i>Obstetrics and Gynecology</i> , 2012, 119, 753-761.	2.4	88
28	COVID-19 Threatens Progress Toward Gender Equity Within Academic Medicine. <i>Academic Medicine</i> , 2021, 96, 813-816.	1.6	88
29	Treatment of Depression and Menopause-Related Symptoms With the Serotonin-Norepinephrine Reuptake Inhibitor Duloxetine. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 943-950.	2.2	81
30	Depression is associated with worse objectively and subjectively measured sleep, but not more frequent awakenings, in women with vasomotor symptoms. <i>Menopause</i> , 2009, 16, 671-679.	2.0	73
31	Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials. <i>Sleep</i> , 2018, 41, .	1.1	67
32	Menopausal quality of life: RCT of yoga, exercise, and omega-3 supplements. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 244.e1-244.e11.	1.3	66
33	Antimüllerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1862-e1871.	3.6	66
34	Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 171.e1-171.e11.	1.3	65
35	Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women. <i>JAMA Psychiatry</i> , 2020, 77, 52.	11.0	65
36	Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making. <i>Menopause</i> , 2015, 22, 247-253.	2.0	64

#	ARTICLE	IF	CITATIONS
37	Trajectories of Vasomotor Symptoms and Carotid Intima Media Thickness in the Study of Women's Health Across the Nation. <i>Stroke</i> , 2016, 47, 12-17.	2.0	63
38	Assessment and treatment of hot flushes and menopausal mood disturbance. <i>Psychiatric Clinics of North America</i> , 2003, 26, 563-580.	1.3	60
39	A Gonadotropin-Releasing Hormone Agonist Model Demonstrates That Nocturnal Hot Flashes Interrupt Objective Sleep. <i>Sleep</i> , 2013, 36, 1977-1985.	1.1	60
40	An Open Trial of Mirtazapine in Menopausal Women with Depression Unresponsive to Estrogen Replacement Therapy. <i>Journal of Women's Health and Gender-Based Medicine</i> , 2001, 10, 999-1004.	1.5	58
41	Methods for the design of vasomotor symptom trials. <i>Menopause</i> , 2014, 21, 45-58.	2.0	57
42	Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN. <i>Journal of the American Heart Association</i> , 2021, 10, e017416.	3.7	56
43	Effects of Estradiol and Venlafaxine on Insomnia Symptoms and Sleep Quality in Women with Hot Flashes. <i>Sleep</i> , 2015, 38, 97-108.	1.1	55
44	Longitudinal Follow-Up of Bipolar Disorder in Women With Premenstrual Exacerbation: Findings From STEP-BD. <i>American Journal of Psychiatry</i> , 2011, 168, 386-394.	7.2	53
45	Longitudinal Follow-up of Reproductive and Metabolic Features of Valproate-Associated Polycystic Ovarian Syndrome Features: A Preliminary Report. <i>Biological Psychiatry</i> , 2006, 60, 1378-1381.	1.3	50
46	Physical activity and risk of vasomotor symptoms in women with and without a history of depression. <i>Menopause</i> , 2006, 13, 553-560.	2.0	50
47	Independent Contributions of Nocturnal Hot Flashes and Sleep Disturbance to Depression in Estrogen-Deprived Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3847-3855.	3.6	50
48	Depressive symptoms across the menopause transition: findings from a large population-based cohort study. <i>Menopause</i> , 2016, 23, 1287-1293.	2.0	48
49	Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. <i>Obstetrics and Gynecology</i> , 2015, 126, 413-422.	2.4	47
50	Hot Flash Frequency and Blood Pressure: Data from the Study of Women's Health Across the Nation. <i>Journal of Women's Health</i> , 2016, 25, 1204-1209.	3.3	47
51	Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes. <i>Menopause</i> , 2010, 17, 908-916.	2.0	45
52	Mood Symptoms After Natural Menopause and Hysterectomy With and Without Bilateral Oophorectomy Among Women in Midlife. <i>Obstetrics and Gynecology</i> , 2012, 119, 935-941.	2.4	45
53	Adverse effects of induced hot flashes on objectively recorded and subjectively reported sleep. <i>Menopause</i> , 2013, 20, 905-914.	2.0	45
54	The Impact of Depot GnRH Agonist on AMH Levels in Healthy Reproductive-Aged Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1961-E1966.	3.6	45

#	ARTICLE	IF	CITATIONS
55	Patterns of depressive disorders across 13 years and their determinants among midlife women: SWAN mental health study. <i>Journal of Affective Disorders</i> , 2016, 206, 31-40.	4.1	45
56	Objective sleep interruption and reproductive hormone dynamics in the menstrual cycle. <i>Sleep Medicine</i> , 2014, 15, 688-693.	1.6	44
57	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 4311-4324.	7.0	44
58	PSYCHOSOCIAL FEATURES ASSOCIATED WITH LIFETIME COMORBIDITY OF MAJOR DEPRESSION AND ANXIETY DISORDERS AMONG A COMMUNITY SAMPLE OF MID-LIFE WOMEN: THE SWAN MENTAL HEALTH STUDY. <i>Depression and Anxiety</i> , 2012, 29, 1050-1057.	4.1	41
59	Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. <i>Menopause</i> , 2020, 27, 498-505.	2.0	41
60	Sleep Trajectories Before and After the Final Menstrual Period in the Study of Women's Health Across the Nation (SWAN). <i>Current Sleep Medicine Reports</i> , 2017, 3, 235-250.	1.4	40
61	Sleep, Health, and Metabolism in Midlife Women and Menopause. <i>Obstetrics and Gynecology Clinics of North America</i> , 2018, 45, 679-694.	1.9	40
62	Menstrual Cycle Dysfunction Associated with Neurologic and Psychiatric Disorders. <i>Annals of the New York Academy of Sciences</i> , 2008, 1135, 219-229.	3.8	37
63	Lifetime History of Depression and Anxiety Disorders as a Predictor of Quality of Life in Midlife Women in the Absence of Current Illness Episodes. <i>Archives of General Psychiatry</i> , 2012, 69, 484.	12.3	37
64	Effects of Yoga and Aerobic Exercise on Actigraphic Sleep Parameters in Menopausal Women with Hot Flashes. <i>Journal of Clinical Sleep Medicine</i> , 2017, 13, 11-18.	2.6	35
65	Menstrual Dysfunction Prior to Onset of Psychiatric Illness Is Reported More Commonly by Women With Bipolar Disorder Than by Women With Unipolar Depression and Healthy Controls. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 297-304.	2.2	35
66	Treatment of Premenstrual Worsening of Depression With Adjunctive Oral Contraceptive Pills. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1954-1962.	2.2	35
67	Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: A randomized controlled trial. <i>Maturitas</i> , 2012, 73, 361-368.	2.4	34
68	Lifelong estradiol exposure and risk of depressive symptoms during the transition to menopause and postmenopause. <i>Menopause</i> , 2017, 24, 1351-1359.	2.0	33
69	Racial/ethnic disparities in women's sleep duration, continuity, and quality, and their statistical mediators: Study of Women's Health Across the Nation. <i>Sleep</i> , 2019, 42, .	1.1	33
70	Placebo Improvement in Pharmacologic Treatment of Menopausal Hot Flashes. <i>Psychosomatic Medicine</i> , 2015, 77, 167-175.	2.0	32
71	Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education. <i>Journal of Clinical Oncology</i> , 2021, 39, 3473-3484.	1.6	29
72	Associations between improvement in genitourinary symptoms of menopause and changes in the vaginal ecosystem. <i>Menopause</i> , 2018, 25, 500-507.	2.0	28

#	ARTICLE	IF	CITATIONS
73	Sexual Function in Women on Estradiol or Venlafaxine for Hot Flashes. <i>Obstetrics and Gynecology</i> , 2014, 124, 233-241.	2.4	27
74	The role of sleep difficulties in the vasomotor menopausal symptoms and depressed mood relationships: an international pooled analysis of eight studies in the InterLACE consortium. <i>Psychological Medicine</i> , 2018, 48, 2550-2561.	4.5	27
75	Impact of Estradiol Variability and Progesterone on Mood in Perimenopausal Women With Depressive Symptoms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e642-e650.	3.6	27
76	Metabolic Activity in the Insular Cortex and Hypothalamus Predicts Hot Flashes: An FDG-PET Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3207-3215.	3.6	26
77	Nocturnal Hot Flashes: Relationship to Objective Awakenings and Sleep Stage Transitions. <i>Journal of Clinical Sleep Medicine</i> , 2016, 12, 1003-1009.	2.6	23
78	Sexual Function in Nondepressed Women Using Escitalopram for Vasomotor Symptoms. <i>Obstetrics and Gynecology</i> , 2012, 119, 527-538.	2.4	22
79	Enrollment of female participants in United States drug and device phase 1-3 clinical trials between 2016 and 2019. <i>Contemporary Clinical Trials</i> , 2022, 115, 106718.	1.8	22
80	Psychosocial and health-related risk factors for depressive symptom trajectories among midlife women over 15 years: Study of Women's Health Across the Nation (SWAN). <i>Psychological Medicine</i> , 2019, 49, 250-259.	4.5	21
81	A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes) Trial. <i>BMJ</i> , 2021, 374, n001147.	1.1	21
82	Menopause and Mood. <i>Clinical Obstetrics and Gynecology</i> , 2004, 47, 576-591.	1.1	20
83	Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition. <i>Maturitas</i> , 2013, 75, 170-174.	2.4	20
84	Effects of Escitalopram on Markers of Bone Turnover: A Randomized Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1732-E1737.	3.6	20
85	Multidimensional sleep health is not cross-sectionally or longitudinally associated with adiposity in the Study of Women's Health Across the Nation (SWAN). <i>Sleep Health</i> , 2020, 6, 790-796.	2.5	18
86	Relation of Daily Urinary Hormone Patterns to Vasomotor Symptoms in a Racially/Ethnically Diverse Sample of Midlife Women: Study of Women's Health Across the Nation. <i>Reproductive Sciences</i> , 2007, 14, 786-797.	2.5	16
87	Does midlife aging impact women's sleep duration, continuity, and timing?: A longitudinal analysis from the Study of Women's Health Across the Nation. <i>Sleep</i> , 2020, 43, .	1.1	16
88	Lights on MsFLASH: a review of contributions. <i>Menopause</i> , 2020, 27, 473-484.	2.0	16
89	Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 53-62.	2.5	15
90	Treatment of Premenstrual Breakthrough of Depression With Adjunctive Oral Contraceptive Pills Compared With Placebo. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 609-614.	1.4	14

#	ARTICLE	IF	CITATIONS
91	Predictors of irritability symptoms in mildly depressed perimenopausal women. Psychoneuroendocrinology, 2021, 126, 105128.	2.7	14
92	A Putative Relationship between Valproic Acid and Polycystic Ovarian Syndrome: Implications for Treatment of Women with Seizure and Bipolar Disorders. Harvard Review of Psychiatry, 2003, 11, 99-108.	2.1	13
93	Effects of Testosterone and Estradiol Deficiency on Vasomotor Symptoms in Hypogonadal Men. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3479-3486.	3.6	13
94	Confirmatory factor analysis of the Insomnia Severity Index (ISI) and invariance across race: a pooled analysis of MsFLASH data. Menopause, 2019, 26, 850-855.	2.0	13
95	Longitudinal Association Between Depressive Symptoms and Multidimensional Sleep Health: The SWAN Sleep Study. Annals of Behavioral Medicine, 2021, 55, 641-652.	2.9	13
96	Should Hormone Therapy Be Used to Prevent Depressive Symptoms During the Menopause Transition?. JAMA Psychiatry, 2018, 75, 125.	11.0	11
97	Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram. Menopause, 2013, 20, 261-268.	2.0	11
98	Associations between sleep and cognitive performance in a racially/ethnically diverse cohort: the Study of Women's Health Across the Nation. Sleep, 2021, 44, .	1.1	9
99	What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Gynecologic Oncology, 2021, 161, 527-534.	1.4	9
100	Reproductive biology and psychotropic treatments in premenopausal women with bipolar disorder. Journal of Clinical Psychiatry, 2007, 68 Suppl 9, 10-5.	2.2	9
101	The Risk of Remaining Silent: Addressing the Current Threats to Women's Health. Women's Health Issues, 2017, 27, 621-624.	2.0	8
102	Screening for Depression in Younger Breast Cancer Survivors: Outcomes From Use of the 9-item Patient Health Questionnaire. JNCI Cancer Spectrum, 2021, 5, pkab017.	2.9	8
103	Influence of the menopausal transition on polysomnographic sleep characteristics: a longitudinal analysis. Sleep, 2021, 44, .	1.1	8
104	Identifying women who share patterns of reproductive hormones, vasomotor symptoms, and sleep maintenance problems across the menopause transition: group-based multi-trajectory modeling in the Study of Women's Health Across the Nation. Menopause, 2021, 28, 126-134.	2.0	8
105	Disparate Rates of New-Onset Depression During the Menopausal Transition in 2 Community-based Populations: Real, or Really Wrong?. American Journal of Epidemiology, 2013, 177, 1148-1156.	3.4	7
106	OR11-03 NT-814, a Non-Hormonal Dual Neurokinin 1,3 Receptor Antagonist Markedly Improves Vasomotor Symptoms in Post-Menopausal Women; Results of a Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Study (SWITCH-1). Journal of the Endocrine Society, 2020, 4, .	0.2	7
107	Trajectory analysis of sleep maintenance problems in midlife women before and after surgical menopause: the Study of Women's Health Across the Nation (SWAN). Menopause, 2020, 27, 278-288.	2.0	7
108	Plasma androgens and the presence and course of depression in a large cohort of women. Translational Psychiatry, 2021, 11, 124.	4.8	7

#	ARTICLE	IF	CITATIONS
109	Sleep and endocrine therapy in breast cancer. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 18, 165-170.	1.4	7
110	Armodafinil for fatigue associated with menopause. <i>Menopause</i> , 2016, 23, 209-214.	2.0	6
111	Shifting Paradigms About Hormonal Risk Factors for Postmenopausal Depression. <i>JAMA Psychiatry</i> , 2016, 73, 111.	11.0	6
112	A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women. <i>Sleep</i> , 2022, 45, .	1.1	6
113	Workshop on normal reference ranges for estradiol in postmenopausal women: commentary from The North American Menopause Society on low-dose vaginal estrogen therapy labeling. <i>Menopause</i> , 2020, 27, 611-613.	2.0	5
114	A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103747.	2.0	5
115	Cardiovascular reactivity and psychological hyperarousal in hot flash-associated insomnia disorder. <i>Menopause</i> , 2019, 26, 728-740.	2.0	4
116	Prescription medications for sleep disturbances among midlife women during 2 years of follow-up: a SWAN retrospective cohort study. <i>BMJ Open</i> , 2021, 11, e045074.	1.9	4
117	Hypothalamic-pituitary-adrenal axis, subjective, and thermal stress responses in midlife women with vasomotor symptoms. <i>Menopause</i> , 2021, 28, 439-443.	2.0	4
118	Sleep Fragmentation and Estradiol Suppression Decrease Fat Oxidation in Premenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3167-e3176.	3.6	4
119	Introduction. <i>Harvard Review of Psychiatry</i> , 2009, 17, 69-71.	2.1	3
120	Trajectory Clustering of Estradiol and Follicle-Stimulating Hormone During the Menopausal Transition Among Women in the Study of Women's Health Across the Nation (SWAN). <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 361-363.	0.4	3
121	Antidepressant use after discontinuation of hormone therapy. <i>Menopause</i> , 2013, 20, 123-125.	2.0	2
122	Response to Eskola et al.. <i>American Journal of Psychiatry</i> , 2015, 172, 797-797.	7.2	2
123	Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 125-135.	2.5	2
124	Brain-derived neurotrophic factor and mood in perimenopausal depression. <i>Journal of Affective Disorders</i> , 2022, 300, 145-149.	4.1	2
125	Concern About the Use of Venlafaxine to Treat Vasomotor Symptoms—Reply. <i>JAMA Internal Medicine</i> , 2015, 175, 658.	5.1	1
126	Sex, Gender, and Precision Medicine—Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 1129.	5.1	1

#	ARTICLE	IF	CITATIONS
127	NAMS 2019 Pre-Meeting Symposium, September 2019, Chicago Illinois: The Perimenopause. Menopause, 2020, 27, 735-745.	2.0	1
128	At menopause, what comes first: the sleepless chicken or the sex?. Menopause, 2021, 28, 606-607.	2.0	1
129	Lowered progesterone metabolite excretion and a variable LH excretion pattern are associated with vasomotor symptoms but not negative mood in the early perimenopausal transition: Study of Women's Health Across the Nation. Maturitas, 2021, 147, 26-33.	2.4	1
130	Effect of Experimentally Induced Sleep Fragmentation and Hypoestrogenism on Fasting Nutrient Utilization in Pre-Menopausal Women. Journal of the Endocrine Society, 2021, 5, A774-A774.	0.2	1
131	Sex and Gender Differences in Health. Annals of Internal Medicine, 2021, 174, 143-144.	3.9	1
132	Response to Harvey and Kornstein Letter. American Journal of Psychiatry, 2011, 168, 989-990.	7.2	0
133	Vasomotor Symptoms and Insulin Resistance in the Study of Women's Health Across the Nation. Obstetrical and Gynecological Survey, 2013, 68, 113-114.	0.4	0
134	BDNF and Mood in Perimenopausal Depression. Biological Psychiatry, 2020, 87, S368-S369.	1.3	0
135	Elinzanetant (NT-814): a novel, non-hormonal dual NK-1,3 receptor antagonist for the treatment of vasomotor symptoms - key findings from the Phase 2 SWITCH-1 study. Maturitas, 2021, 152, 71.	2.4	0
136	NAMS 2021 Utian Translational Science SymposiumSeptember 2021, Washington, DCCharting the path to health in midlife and beyond: the biology and practice of wellness. Menopause, 2022, 29, 504-513.	2.0	0
137	P688. Evoked Subjective and Hypothalamic-Pituitary-Adrenal (HPA) Axis Stress Responses in Non-Depressed Midlife Women: Relationship to Vasomotor Symptom Persistence and Insomnia. Biological Psychiatry, 2022, 91, S369.	1.3	0